The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
On the 2025 American Society of Hematology (ASH) Annual Assembly and Exposition, researchers introduced new findings which have the potential to meaningfully...
Gastric most cancers therapy could be particularly difficult as a result of sufferers typically battle with consuming, sustaining weight, and managing nausea,...
Shortly after starting therapy for stage 3 inflammatory breast most cancers, Lindsey Gunter began experiencing uncommon chemotherapy unintended effects so intense that...
